MA39495A - Formulations d'aripiprazole présentant des vitesses d'injection plus élevées - Google Patents

Formulations d'aripiprazole présentant des vitesses d'injection plus élevées

Info

Publication number
MA39495A
MA39495A MA039495A MA39495A MA39495A MA 39495 A MA39495 A MA 39495A MA 039495 A MA039495 A MA 039495A MA 39495 A MA39495 A MA 39495A MA 39495 A MA39495 A MA 39495A
Authority
MA
Morocco
Prior art keywords
ariipiprazole
formulations
injection rates
higher injection
rates
Prior art date
Application number
MA039495A
Other languages
English (en)
Inventor
Migali B Hickey
Jennifer Vandiver
Original Assignee
Alkermes Pharma Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Ltd filed Critical Alkermes Pharma Ireland Ltd
Publication of MA39495A publication Critical patent/MA39495A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA039495A 2014-03-20 2015-03-19 Formulations d'aripiprazole présentant des vitesses d'injection plus élevées MA39495A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461955976P 2014-03-20 2014-03-20

Publications (1)

Publication Number Publication Date
MA39495A true MA39495A (fr) 2015-09-24

Family

ID=54141031

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039495A MA39495A (fr) 2014-03-20 2015-03-19 Formulations d'aripiprazole présentant des vitesses d'injection plus élevées

Country Status (12)

Country Link
US (7) US9452131B2 (fr)
EP (1) EP3119399A4 (fr)
JP (2) JP6524110B2 (fr)
CN (2) CN106132415A (fr)
AU (2) AU2015231278B2 (fr)
BR (1) BR112016021535A8 (fr)
CA (1) CA2943213C (fr)
IL (2) IL247517B (fr)
MA (1) MA39495A (fr)
MX (2) MX2016012041A (fr)
RU (1) RU2688233C2 (fr)
WO (1) WO2015143145A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010266018B2 (en) 2009-06-25 2014-01-09 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
EP4327872A3 (fr) 2011-03-18 2024-07-10 Alkermes Pharma Ireland Limited Compositions pharmaceutiques comprenant des esters de sorbitan
NZ630643A (en) 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
NZ630428A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
ES2764383T3 (es) 2012-03-19 2020-06-03 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de glicerol
CA2885196C (fr) 2012-09-19 2021-06-22 Alkermes Pharma Ireland Limited Compositions pharmaceutiques ayant une plus grande stabilite au stockage
WO2015143145A1 (fr) 2014-03-20 2015-09-24 Alkermes Pharma Ireland Limited Formulations d'aripiprazole présentant des vitesses d'injection plus élevées
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
WO2019020821A1 (fr) * 2017-07-28 2019-01-31 Interquim, S.A. Procédé de préparation d'aripiprazole lauroxil
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
JP7532367B2 (ja) * 2018-12-04 2024-08-13 バンダ・ファーマシューティカルズ・インコーポレイテッド イロペリドンの持効性投与

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2418499A (en) 1944-06-20 1947-04-08 Du Pont 2-alkoxymethylmercapto-thiazoles and thiazolines and a process for preparing the same
GB849541A (en) 1956-02-23 1960-09-28 Rohm & Haas Preparation of unsaturated cyclic urea derivatives
DE1273533B (de) 1962-09-08 1968-07-25 Hoechst Ag Verfahren zur Herstellung von N-(ª‡-Alkoxy-alkyl)-carbonsaeureamiden
NL128370C (fr) 1964-08-28
US3452034A (en) 1967-03-09 1969-06-24 American Cyanamid Co Substituted 2-(1,3,4-thiadiazol-2-yl)-4(5)-nitroimidazoles
US3573308A (en) 1969-04-03 1971-03-30 Hoffmann La Roche 3-lower alkoxy methyl-3,4-dihydro-4-hydroxy-4-aryl quinazolin-2(1h) ones and related compounds
US3957808A (en) 1969-09-03 1976-05-18 Rohm And Haas Company 3-alkoxyisothiazoles
US3998815A (en) 1974-06-24 1976-12-21 Interx Research Corporation 1-hydrocarbonoyloxymethyl-3-carbamoyl or 3-carboethoxy-pyridinium salts
US4727151A (en) 1974-06-24 1988-02-23 Interx Research Corporation Labile quaternary ammonium salts as prodrugs
US4204065A (en) 1975-09-22 1980-05-20 Interx Research Corporation Soft quaternary surface active agents and method of using same
JPS5331676A (en) 1976-09-06 1978-03-25 Mitsui Toatsu Chem Inc Uracil derivatives and their preparation
US4260769A (en) 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPS568318A (en) 1979-06-28 1981-01-28 Janssen Pharmaceutica Nv Non oral long acting composition of haloperidol and bromperidol derivative
DE3149010A1 (de) 1981-12-10 1983-07-07 A. Nattermann & Cie GmbH, 5000 Köln (+)-2-(1-(2,6-dichlorphenoxy)-ethyl)-1,3- diazacyclopent-2-en, dessen herstellung und seine verwendung in pharamazeutischen praeparaten
US4428935A (en) 1982-05-24 1984-01-31 Pfizer Inc. Penicillanic acid dioxide prodrug
IT1212743B (it) 1983-05-17 1989-11-30 Dompe Farmaceutici Spa Sali quaternari di derivati di benzo[ 1,4 ]diazepinonici,pirido [1,4]benzodiazepinonici,prido [1,5]benzodiazepinonici e loro atti vita' farmacologica
JPS602331A (ja) 1983-06-20 1985-01-08 Yoshino Kogyosho Co Ltd 飽和ポリエステル樹脂製壜の成形方法
US4760057A (en) 1983-06-23 1988-07-26 Merck & Co., Inc. (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs
DK302883D0 (da) 1983-06-30 1983-06-30 Hans Bundgaard Allopurinol prodrugs
DE3544134A1 (de) 1984-12-15 1986-06-19 Mitsubishi Chemical Industries Ltd., Tokio/Tokyo Verfahren zur herstellung von n-((alpha)-alkoxyethyl) pyrrolidon
GB8513754D0 (en) 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives
DK588486A (da) 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US4925860A (en) 1987-08-05 1990-05-15 E. I. Du Pont De Nemours And Company Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5350747A (en) 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
WO1991000863A1 (fr) 1989-07-07 1991-01-24 Pfizer Inc. Agents antipsychotiques a base de piperazine d'heteroaryle
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5206386A (en) 1991-03-20 1993-04-27 Isp Investments Inc. Controlled release N-substituted pyrrolidone esters and process for the use thereof
AU645681B2 (en) 1991-05-02 1994-01-20 John Wyeth & Brother Limited Piperazine derivatives
TW226016B (fr) 1991-12-30 1994-07-01 Sterling Winthrop Inc
US5462934A (en) 1992-03-09 1995-10-31 Takeda Chemical Industries Condensed heterocyclic ketone derivatives and their use
AU4534593A (en) 1992-06-12 1994-01-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5719303A (en) 1993-03-08 1998-02-17 Eisai Co., Ltd. Phosphonic acid derivatives
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
DE4439493A1 (de) 1994-10-25 1996-05-02 Schering Ag Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln
JP3571795B2 (ja) 1995-04-18 2004-09-29 株式会社日本触媒 Ｎ−（１−アルキルオキシアルキル）カルバメート類の気相分子内脱アルコール反応用触媒およびｎ−ビニルカルバメート類の製造方法
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
PL187926B1 (pl) 1996-03-25 2004-11-30 Lilly Co Eli Kompozycja farmaceutyczna do leczenia bólu
DE19619819A1 (de) 1996-05-16 1997-11-20 Boehringer Mannheim Gmbh Neue Thiazolidindione, Verfahren zu ihrer Herstellung und diese enthaltenden Arzneimittel
EP0925061B1 (fr) 1996-08-22 2005-12-28 Jagotec Ag Compositions comprenant des microparticules de substances insolubles dans l'eau et procede de preparation associe
DE69819721T2 (de) 1997-06-13 2004-09-23 Cydex Inc., Overland Park Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden
UA73715C2 (en) 1997-09-30 2005-09-15 Lilly Co Eli Pharmaceutically acceptable formulation of olanzapine pamoate and its use for treatment
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
DE69822514T2 (de) 1997-12-31 2005-03-24 The University Of Kansas, Lawrence Wasserlösliche pro-pharmaka von arzneistoffen, die ein tertiäres amin enthalten, und verfahren zu ihrer herstellung
EP1114028B1 (fr) 1998-08-26 2006-11-29 Aventis Pharma Limited Bicycles aza modulant l'inhibition de l'adhesion cellulaire
FR2783519B1 (fr) 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2311734C (fr) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Forme pharmaceutique orale a dissolution ultra-rapide
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
US6656505B2 (en) 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
US20030049320A1 (en) 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
ES2231708T3 (es) 2001-02-14 2005-05-16 Warner-Lambert Company Llc Benzotiadicinas inhibidoras de metaloproteinasa de matriz.
US20060293217A1 (en) 2001-03-19 2006-12-28 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained release
US20020176841A1 (en) 2001-03-19 2002-11-28 Praecis Pharmaceuticals Inc. Pharmaceutical formulations for sustained release
CA2443350A1 (fr) 2001-04-03 2002-12-05 Aryx Therapeutics Opioides a action ultrabreve pour application transdermique
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
EP2033953A1 (fr) 2002-02-15 2009-03-11 Glaxo Group Limited Modulateurs des récepteurs vanilloides
JP4667867B2 (ja) 2002-08-02 2011-04-13 メルク・シャープ・エンド・ドーム・コーポレイション 置換フロ［２，３−ｂ］ピリジン誘導体
SI1542668T1 (sl) 2002-08-20 2009-08-31 Bristol Myers Squibb Co Aripiprazol sestavljena formulacija in postopek
PL375981A1 (en) 2002-09-17 2005-12-12 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
US7148211B2 (en) 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
CA2510181C (fr) 2002-12-18 2011-03-08 Algorx Pharmaceuticals, Inc. Administration de capsaicinoides
AU2003301190A1 (en) 2002-12-18 2004-07-14 Algorx Administration of capsaicinoids
DE10303669A1 (de) 2003-01-28 2004-07-29 Hans-Knöll-Institut für Naturstoff-Forschung e.V. Tetraalkylammoniumsalze vom Kohlensäureestertyp, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
NZ542475A (en) 2003-04-03 2009-04-30 Semafore Pharmaceuticals Inc PI-3 kinase inhibitor prodrugs
CA2526562C (fr) 2003-05-23 2011-06-28 Otsuka Pharmaceutical Co., Ltd. Derives de carbostyrile et psychoregulateurs pour traiter les troubles de l'humeur
NZ545289A (en) 2003-07-24 2008-05-30 Merial Ltd Vaccine formulations comprising an oil-in-water emulsion
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
JP4231051B2 (ja) 2003-08-29 2009-02-25 株式会社東芝 測定対象物質の濃度測定方法、測定対象物質の濃度測定用キット及びセンサチップ
CN1870980B (zh) * 2003-10-23 2010-06-23 大冢制药株式会社 控释无菌阿立哌唑注射剂和方法
CA2551346A1 (fr) 2003-12-31 2005-07-21 Warner-Lambert Company Llc Derives de piperidine et de piperazine n-substitues
BRPI0507609A (pt) 2004-02-13 2007-07-03 Pfizer Prod Inc combinações terapêuticas de anti-psicóticos atìpicos com antagonistas de fator de liberação de corticotropina
US7169803B2 (en) 2004-03-15 2007-01-30 Bristol-Myers Squibb Company N-substituted prodrugs of fluorooxindoles
US7119214B2 (en) 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
GB2413795A (en) 2004-05-05 2005-11-09 Cipla Ltd Process for the preparation of rosiglitazone
WO2006037090A2 (fr) 2004-09-28 2006-04-06 Purdue Research Foundation Promedicaments contenant des conjugues de phosphate-medicament et des analogues de ceux-ci
KR20130030305A (ko) 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
EP1848541A4 (fr) 2005-02-07 2013-01-16 Pharmalight Inc Procede et dispositif d'administration ophtalmique d'ingredients pharmaceutiquement actifs
WO2006090273A2 (fr) 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones et composes relatifs a liants ceto ou hydroxyl destines au traitement de la schizophrenie
US8283352B2 (en) 2005-06-13 2012-10-09 Dainippon Sumitomo Pharma Co., Ltd. Solubilization preparation
EP1933814A2 (fr) 2005-09-15 2008-06-25 Elan Pharma International Limited Formulations aripiprazoliques nanoparticulaires
EP1777222A1 (fr) 2005-09-22 2007-04-25 Galantos Pharma GmbH Inhibiteurs de la cholinesterase avec une perméabilité améliorée de la barrière ématoencéphalique pour le traitement de troubles cognitifs
KR20080053398A (ko) 2005-10-31 2008-06-12 화이자 프로덕츠 인크. 7-[4-(4-나프탈렌-1-일-피페라진-1-일)-부톡시]-3,4-디하이드로-1ｈ-[1,8]나프티리딘-2-온의 결정성 염
US20070185069A1 (en) 2005-11-14 2007-08-09 Plum Stacy M Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
BRPI0715445A2 (pt) 2006-08-31 2014-05-13 Solvay Pharm Bv Uso de um composto de bifeprunox, e, kit de titulação
US20090068290A1 (en) 2006-08-31 2009-03-12 Michel Bourin Bifeprunox doses for treating schizophrenia
CL2007002684A1 (es) 2006-09-15 2008-06-27 Astrazeneca Ab Targacept Inc Combinacion que comprende un antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina; composicion farmaceutica que la comprende; kit farmaceutico; y uso para tratar perjuicio cognitivo y/o trastorno psicoticos.
US20090291134A1 (en) 2006-11-21 2009-11-26 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases
WO2008070149A2 (fr) 2006-12-05 2008-06-12 Neurogesx, Inc. Promédicaments et procédés pour les fabriquer et les utiliser
EP2120909A2 (fr) 2006-12-15 2009-11-25 Ordway Research Institute Traitements de maladies résistantes aux thérapies et combinaisons médicamenteuses pour traiter celles-ci
EP1961412A1 (fr) 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Systèmes auto-microémulsifiants pour l'administration de médicaments
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
US20090053329A1 (en) 2007-03-19 2009-02-26 Acadia Pharmaceuticals, Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
UA96015C2 (en) 2007-04-04 2011-09-26 Mepk Шарп Энд Доме Корп. Therapeutic agents
US20100292316A1 (en) 2007-07-18 2010-11-18 Research Development Foundation Improved therapeutic methods and compositions comprising chroman ring compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
BRPI0815280A2 (pt) * 2007-08-27 2018-11-27 Biogenerix Ag medicamento que compreende uma formulação líquida aquosa de g-csf, receptáculo para a administração de medicamentos líquidos, seringa ou ampola, kit para a administração parenteral de g-csf
WO2009052467A1 (fr) 2007-10-19 2009-04-23 Board Of Regents Of The University Of Texas System Procédés d'identification d'une résistance à l'inhibiteur de pi-3 kinase
CL2008003305A1 (es) 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
DK2234617T3 (da) 2007-12-19 2021-05-25 Janssen Pharmaceutica Nv Doseringsskema forbundet med langtidsvirkende injicerbare paliperidonestere
WO2009086303A2 (fr) 2007-12-21 2009-07-09 University Of Rochester Procédé permettant de modifier la durée de vie d'organismes eucaryotes
US9161943B2 (en) 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
WO2009126931A2 (fr) 2008-04-11 2009-10-15 Xvasive, Inc. Thérapie combinatoire pour trouble bipolaire
EP2323622A1 (fr) 2008-09-03 2011-05-25 Vertex Pharmaceuticals Incorporated Co-cristaux et formulations pharmaceutiques les comprenant
US8017515B2 (en) 2008-12-10 2011-09-13 Stats Chippac, Ltd. Semiconductor device and method of forming compliant polymer layer between UBM and conformal dielectric layer/RDL for stress relief
CA2750400A1 (fr) 2009-01-26 2010-07-29 Egalet A/S Formulations a liberation controlee avec efficacite continue
TW201105667A (en) 2009-05-08 2011-02-16 Cytopathfinder Inc Dihydronaphthyridinyl and related compounds for use in treating ophthalmological disorders
AU2010266018B2 (en) 2009-06-25 2014-01-09 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
EP2445343B1 (fr) 2009-06-25 2021-08-04 Alkermes Pharma Ireland Limited Promédicaments de composés nh acides
BRPI1015039A2 (pt) 2009-07-01 2016-04-12 Bayer Materialscience Ag método para fabricação de um polímero de poliuretano com poliéster-polióis compreendendo grupos terminais hidroxila secundários.
JP2013509435A (ja) 2009-10-30 2013-03-14 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型注入可能パリペリドンエステルに関連した投与レジメン
US20110166156A1 (en) 2010-01-07 2011-07-07 Alkermes, Inc. Prodrugs for the Treatment of Schizophrenia and Bipolar Disease
WO2011084849A1 (fr) 2010-01-07 2011-07-14 Alkermes, Inc. Promédicaments de la diaryldiazépine destinés au traitement d'affections neurologiques et psychologiques
AU2010339691B2 (en) 2010-01-07 2015-04-02 Alkermes Pharma Ireland Limited Prodrugs of heteraromatic compounds
WO2011084851A1 (fr) 2010-01-07 2011-07-14 Alkermes, Inc. Promédicaments de l'asénapine
AU2010339689B2 (en) 2010-01-07 2015-02-19 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
CN104111233B (zh) 2010-02-16 2017-09-15 浜松光子学株式会社 气体浓度计算装置及气体浓度测量模块
WO2011140183A1 (fr) 2010-05-04 2011-11-10 Alkermes, Inc. Procédé de synthèse de lactames oxydés
NZ604423A (en) 2010-06-24 2015-01-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
CN102525915B (zh) * 2010-12-14 2016-09-28 江苏豪森药业集团有限公司 一种持续释放的注射制剂及其制备方法和用途
EP4327872A3 (fr) 2011-03-18 2024-07-10 Alkermes Pharma Ireland Limited Compositions pharmaceutiques comprenant des esters de sorbitan
ES2764383T3 (es) * 2012-03-19 2020-06-03 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de glicerol
NZ630643A (en) * 2012-03-19 2017-08-25 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising fatty acid esters
NZ630428A (en) 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
CA2885196C (fr) 2012-09-19 2021-06-22 Alkermes Pharma Ireland Limited Compositions pharmaceutiques ayant une plus grande stabilite au stockage
WO2015143145A1 (fr) 2014-03-20 2015-09-24 Alkermes Pharma Ireland Limited Formulations d'aripiprazole présentant des vitesses d'injection plus élevées

Also Published As

Publication number Publication date
US20160263111A1 (en) 2016-09-15
IL247517A0 (en) 2016-11-30
CN110368360A (zh) 2019-10-25
US20170157117A1 (en) 2017-06-08
US9452131B2 (en) 2016-09-27
EP3119399A1 (fr) 2017-01-25
NZ723869A (en) 2020-09-25
US10085980B2 (en) 2018-10-02
US10238651B2 (en) 2019-03-26
US9526726B2 (en) 2016-12-27
RU2016141055A3 (fr) 2018-11-02
AU2020202577B2 (en) 2022-07-07
US11406632B2 (en) 2022-08-09
BR112016021535A8 (pt) 2021-07-20
JP6524110B2 (ja) 2019-06-05
AU2015231278A1 (en) 2016-09-22
WO2015143145A1 (fr) 2015-09-24
IL247517B (en) 2021-09-30
CN106132415A (zh) 2016-11-16
MX2020010839A (es) 2020-11-06
US20230026422A1 (en) 2023-01-26
EP3119399A4 (fr) 2017-09-27
JP6896015B2 (ja) 2021-06-30
BR112016021535A2 (pt) 2017-08-15
NZ762767A (en) 2023-09-29
JP2017507992A (ja) 2017-03-23
US20180369239A1 (en) 2018-12-27
AU2015231278B2 (en) 2020-01-23
US10813928B2 (en) 2020-10-27
US20190167673A1 (en) 2019-06-06
CA2943213A1 (fr) 2015-09-24
IL285227A (en) 2021-09-30
US11931355B2 (en) 2024-03-19
CA2943213C (fr) 2022-07-05
JP2019123749A (ja) 2019-07-25
RU2688233C2 (ru) 2019-05-21
US20150265529A1 (en) 2015-09-24
AU2020202577A1 (en) 2020-05-07
RU2016141055A (ru) 2018-04-20
MX2016012041A (es) 2017-01-19
RU2019114425A (ru) 2019-07-30
US20200289504A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
DK3587417T3 (da) 1,3-thiazol-2-yl-substituerede benzamider
MA39495A (fr) Formulations d'aripiprazole présentant des vitesses d'injection plus élevées
DK3171700T3 (da) Infusionsanlæg
IL251976A0 (en) Phage therapy
UY4430S (es) “motocicleta”.
MA43873A (fr) Dspositif d'injection
DK3134483T3 (da) Vandig sammensætning med forbedret brudforlængelse
UA32431S (uk) Стрем'янка
UA31292S (uk) Логотип «маланка»
UA30549S (uk) Логотип «дваждыдва»
ES1135060Y (es) " arado "
UA30935S (uk) Логотип «inmag»
ITUB201551290U1 (it) Ovie' oviel
UA29959S (uk) Логотип «киарм»
UA30368S (uk) Логотип «аптека копійка»
UA28003S (uk) Логотип «wаlfіх»
UA32536S (uk) Логотип «нямушка»
UA29700S (uk) Пляшка «куманець»
UA30401S (uk) Пляшка «триангулар»
UA31215S (uk) Каструля «іcook»
FR3027787B1 (fr) Seau'good
UA28620S (uk) Логотип «борщ»
UA31408S (uk) Етикетка для кави «фреш-кофе»
UA31320S (uk) Етикетка «bratz»
UA30652S (uk) Логотип «захист»